NASDAQ : XLO

Xilio Therapeutics, Inc. — Company profile

Healthcare · Biotechnology · United States

Last price 8.03 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 52.84M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Company profile

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company’s pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.

Details

NameXilio Therapeutics, Inc.
SectorHealthcare
IndustryBiotechnology
Employees76
Founded2016
Ipo Date2021-10-22
CeoRene Russo
CountryUnited States
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
Ipo Price16.00
IsinUS98422T2096
Cusip98422T209
Cik1840233
Sic2834
Stock TypeCommon Stock

Key executives

NameTitle
Dr. Rene Russo BCPS, Pharm.D.President, Chief Executive Officer and Director
Christopher FrankenfieldChief Financial Officer and Chief Operating Officer
Kevin M. BrennanSenior Vice President of Finance and Accounting
Dr. Uli Bialucha Ph.D.Chief Scientific Officer
Nathan McBrideChief Information Officer
Benjamin S. Harshbarger J.D.Chief Legal Officer
Dr. Scott Coleman Ph.D.Chief Development Officer
Ruth du MoulinSenior Vice President of Medical Affairs
Dr. Yariv Houvras M.D., Ph.D.Chief Medical Officer

Contact

Address828 Winter Street, Suite 300, Waltham, Massachusetts 02451, United States
Phone857 524 2466
Websitehttps://xiliotx.com